中国实用神经疾病杂志2026，Vol.29Issue(2)：195-199,5.DOI:10.12083/SYSJ.251632
急性脑梗死患者抗血小板治疗史对溶栓后替罗非班序贯治疗效果及安全性的影响
Effect of antiplatelet therapy on the efficacy and safety of tirofiban sequential therapy following thrombolysis in patients with acute ischemic stroke
摘要
Abstract
Objective To investigate the effect of pre-onset antiplatelet therapy history on the efficacy and safety of intravenous tirofiban initiated 2 hours after thrombolysis in patients with acute ischemic stroke(AIS).Methods This retrospective study included 48 AIS patients who underwent thrombolysis within the therapeutic window and subsequently received intravenous tirofiban,which was started 2 hours after thrombolysis and continued for 24-72 hours,at the Second Affiliated Hospital of Zhengzhou University between March 2021 and April 2022.Patients were divided into antiplatelet therapy group and non-antiplatelet therapy group according to whether they were receiving antiplatelet therapy before the onset of the disease.The observed primary endpoints included:① Safety:symptomatic intracranial hemorrhage,uncontrolled bleeding at other sites,the changes in platelet count and coagulation-related parameters before and after treatment.② Efficacy:short-term efficacy assessed by NIHSS score,long-term efficacy assessed by mRS score.Results Totally 44 patients were ultimately included,with 22 patients in each group(antiplatelet therapy group and non-antiplatelet therapy group).There was no significant difference in NIHSS score and effective rate at 24 hours after treatment between the two groups(P>0.05).Furthermore,there were no significant differences between the two groups in 90-day prognosis,recurrence within 90 days,or mortality from cardiovascular and cerebrovascular diseases(P>0.05).There were no significant differences in the incidence of sICH,bleeding rates at other sites,or post-treatment platelet counts and four coagulation parameters between the two groups(P>0.05).Conclusion Whether patients undergoing antiplatelet therapy before onset didn't significantly affect the clinical outcomes of tirofiban administration after intravenous thrombolysis.It should not be considered as a contraindication for tirofiban use after intravenous thrombolysis.It can be used in a sequential manner in clinical practice.关键词
急性脑梗死/抗血小板治疗/溶栓治疗/替罗非班/安全性/有效性Key words
Acute cerebral infarction/Antiplatelet therapy/Thrombolytic therapy/Tirofiban/Safety/Effectiveness分类
医药卫生引用本文复制引用
薛孟馨,王彩娥,张会,郭平平,王兆国,杨鹿奎,王亚军,李桂芳,薛孟周..急性脑梗死患者抗血小板治疗史对溶栓后替罗非班序贯治疗效果及安全性的影响[J].中国实用神经疾病杂志,2026,29(2):195-199,5.基金项目
国家自然科学基金面上项目(编号:82071331 （）
81870942) （）
